Today, DNAnexus reveals a new identity system, marking its evolution from processing omics results to omics intelligence. This new brand reflects a period of technological innovation, milestones in customer satisfaction, and remarkable growth, including recognition as one of the fastest growing companies in America as an Inc. 5000 member. Working with pharmaceutical, diagnostic, healthcare, biobank, and government organizations, the company helps manage and interpret complex biological data to support scientific discovery and real-world results.

“The convergence of omics and AI is the largest opportunity in medicine today, but also the one most likely to stall,” said Thomas Laur, CEO of DNAnexus. “Our new brand elements reflect where DNAnexus is today, as the data layer where omics and AI converge, and is built on the pedigree we’ve earned pioneering omics data intelligence across the most ambitious life science programs.”

Omics data continues to compound 38% annually, and as more organizations adopt AI agents, there is a greater need for structured data and reliable governance frameworks. Generalized infrastructure faces challenges with omics data due to scale, biological complexity, and regulatory requirements. Variations in data formats and annotations can make it difficult to combine datasets, maintain data integrity, interpret findings, and prepare information for AI applications.

DNAnexus enables life science and healthcare organizations to transform growing volumes of omics data into faster discoveries, better outcomes and, ultimately, cures. DNAnexus has demonstrated proven results across real-world applications including:

  • AI-Driven Drug Discovery: translational stack that compresses the time from first access to an evidence-backed list of candidate response genes from nine months to four weeks.

  • Diagnostic Testing at Scale: infrastructure for the modern diagnostics lifecycle that runs production tests 80% faster at 20% lower cost.

  • High Stakes Regulatory Science: leading government organizations like the FDA, ARPA-H, and the National Cancer Institute run their most sensitive science on DNAnexus, with secure collaboration across agencies and industry and AI that never leaves the security boundary.

Their solution is led by three principles: Decode, Discover, and Deliver. These principles connect the platform’s technology to its purpose of advancing scientific discovery and precision health.

  • Decode: Transform fragmented omics into standardized, structured, queryable, AI-ready data assets allowing you to understand biology at the molecular level.

  • Discover: Surface insights at speed, from target and biomarker discovery to population-scale research, with analytics on an AI-native substrate.

  • Deliver: Move discoveries into regulated, real-world impact on a security and compliance framework trusted across pharma, diagnostics providers, health systems, biobanks, and regulators.

The world’s leading organizations across pharmaceutical, diagnostics, healthcare, biobanks, and government have placed their trust and partnered with DNAnexus. Its ecosystem includes Sanofi, Moderna, Biogen, GSK, Myriad Genetics, Natera, Labcorp, UCSF, and City of Hope.

“Collaboration across the healthcare ecosystem is a fundamental driver of innovation. By partnering with organizations and companies across the continuum that share our mission, we are advancing the speed and efficacy of scientific research and delivering on the promise of more discoveries and better outcomes,” said Laur.

For more information, visit www.dnanexus.com.

About DNAnexus

DNAnexus is the global standard for omics intelligence. Founded in 2009 with a singular commitment to omics, DNAnexus has become the trusted foundation where the world’s omics data and AI converge to advance human health. Pharma, diagnostics, health systems, biobanks, and government agencies rely on DNAnexus to decode fragmented omics into AI-ready data, discover new therapies faster and deliver them as regulated, real-world impact for the people they serve. More than 64,000 researchers across 54 countries and 130+ enterprise customers run regulatory-grade omics work on DNAnexus, across more than 140 petabytes of data. Learn more at dnanexus.com or follow @DNAnexus.

Media gallery

About The Author
Business Wire